SE9903028D0 - New use - Google Patents

New use

Info

Publication number
SE9903028D0
SE9903028D0 SE9903028A SE9903028A SE9903028D0 SE 9903028 D0 SE9903028 D0 SE 9903028D0 SE 9903028 A SE9903028 A SE 9903028A SE 9903028 A SE9903028 A SE 9903028A SE 9903028 D0 SE9903028 D0 SE 9903028D0
Authority
SE
Sweden
Prior art keywords
chf
stroke
diabetes
heart failure
congestive heart
Prior art date
Application number
SE9903028A
Other languages
English (en)
Swedish (sv)
Inventor
Gilles Dagenais
Hertzel Gerstein
Anders Ljunggren
Salim Yusuf
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20416770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9903028(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9903028A priority Critical patent/SE9903028D0/xx
Publication of SE9903028D0 publication Critical patent/SE9903028D0/xx
Priority to BR0013540-2A priority patent/BR0013540A/pt
Priority to DK08004265.8T priority patent/DK1925303T3/en
Priority to TR2002/02464T priority patent/TR200202464T2/xx
Priority to TR2002/00518T priority patent/TR200200518T2/xx
Priority to PL00353066A priority patent/PL353066A1/xx
Priority to PT80042658T priority patent/PT1925303E/pt
Priority to DE60023518.1T priority patent/DE60023518T3/de
Priority to CNB008110700A priority patent/CN100408093C/zh
Priority to EP00965898.0A priority patent/EP1212081B2/fr
Priority to EP08004265.8A priority patent/EP1925303B1/fr
Priority to PT04006330T priority patent/PT1437131E/pt
Priority to UA2002032397A priority patent/UA76702C2/uk
Priority to HU0202461A priority patent/HU229107B1/hu
Priority to TR2002/02467T priority patent/TR200202467T2/xx
Priority to AT04006330T priority patent/ATE554761T1/de
Priority to MXPA02001633A priority patent/MXPA02001633A/es
Priority to SI200030766T priority patent/SI1212081T2/sl
Priority to AT00965898T priority patent/ATE307604T1/de
Priority to SI200031084T priority patent/SI1925303T1/sl
Priority to CNA2008101259535A priority patent/CN101537181A/zh
Priority to RU2002107673/15A priority patent/RU2272651C2/ru
Priority to IL148126A priority patent/IL148126A/en
Priority to AU76484/00A priority patent/AU7648400A/en
Priority to TR2002/02466T priority patent/TR200202466T2/xx
Priority to CZ20020644A priority patent/CZ303433B6/cs
Priority to SI200031069T priority patent/SI1437131T1/sl
Priority to JP2001519887A priority patent/JP4843172B2/ja
Priority to ES04006330T priority patent/ES2386141T3/es
Priority to ES00965898.0T priority patent/ES2250192T5/es
Priority to EP04006330A priority patent/EP1437131B1/fr
Priority to DK04006330.7T priority patent/DK1437131T3/da
Priority to NZ571901A priority patent/NZ571901A/en
Priority to EP10010670A priority patent/EP2277519A3/fr
Priority to RS3602A priority patent/RS52907B/en
Priority to SK270-2002A priority patent/SK288239B6/sk
Priority to PCT/EP2000/008341 priority patent/WO2001015673A2/fr
Priority to TR2002/02463T priority patent/TR200202463T2/xx
Priority to EEP200200085A priority patent/EE05130B1/xx
Priority to CA002382387A priority patent/CA2382387C/fr
Priority to KR1020027002521A priority patent/KR20020060167A/ko
Priority to KR1020087007837A priority patent/KR20080035703A/ko
Priority to ES08004265.8T priority patent/ES2525699T3/es
Priority to DK00965898.0T priority patent/DK1212081T4/da
Priority to MEP-282/08A priority patent/MEP28208A/xx
Priority to YU3602A priority patent/YU3602A/sh
Priority to BG11047909A priority patent/BG110479A/bg
Priority to BG106319A priority patent/BG66115B1/bg
Priority to NO20020850A priority patent/NO329245B1/no
Priority to ZA200201471A priority patent/ZA200201471B/xx
Priority to HR20020169A priority patent/HRP20020169A2/hr
Priority to HK03102600.5A priority patent/HK1050327A1/xx
Priority to AU2005203694A priority patent/AU2005203694A1/en
Priority to RU2005128124/15A priority patent/RU2378018C2/ru
Priority to UAA200601774A priority patent/UA88270C2/ru
Priority to US11/415,137 priority patent/US20060194868A1/en
Priority to US12/027,938 priority patent/US20080125472A1/en
Priority to AU2009200551A priority patent/AU2009200551B2/en
Priority to US12/457,589 priority patent/US20090258919A1/en
Priority to US12/615,588 priority patent/US20100267798A1/en
Priority to NO20100569A priority patent/NO20100569L/no
Priority to US12/957,777 priority patent/US20110263619A1/en
Priority to CY20121100657T priority patent/CY1112987T1/el
Priority to US13/673,852 priority patent/US20130317047A1/en
Priority to CY20141101082T priority patent/CY1115869T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9903028A 1999-08-27 1999-08-27 New use SE9903028D0 (sv)

Priority Applications (65)

Application Number Priority Date Filing Date Title
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use
BR0013540-2A BR0013540A (pt) 1999-08-27 2000-08-25 Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
DK08004265.8T DK1925303T3 (en) 1999-08-27 2000-08-25 Use of the angiotensin II type 1 receptor antagonists for the prevention of diabetes
TR2002/02464T TR200202464T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar
TR2002/00518T TR200200518T2 (tr) 1999-08-27 2000-08-25 Felç, Diyabet ve/veya Konjesif Kalp Yetmezliğinin Önlenmesinde Kullanılan Farmolojik Formulasyonlar
PL00353066A PL353066A1 (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
PT80042658T PT1925303E (pt) 1999-08-27 2000-08-25 Utilização de antagonistas do receptor tipo 1 da angiotensina ii para a prevenção de diabetes
DE60023518.1T DE60023518T3 (de) 1999-08-27 2000-08-25 Verwendung von ramipril zur prophylaxe von kongestivem herzversagen
CNB008110700A CN100408093C (zh) 1999-08-27 2000-08-25 血管紧张素转化酶抑制剂在制备预防或降低充血性心衰的药物中的用途
EP00965898.0A EP1212081B2 (fr) 1999-08-27 2000-08-25 Utilisations de ramipril pour prevenir l'insuffisance cardiaque globale
EP08004265.8A EP1925303B1 (fr) 1999-08-27 2000-08-25 Utilisation d'antagonistes du récepteur Angiotensin II Type 1 pour prévenir le diabète
PT04006330T PT1437131E (pt) 1999-08-27 2000-08-25 Utilização de ramipril para a prevenção de diabetes num doente sem insuficiência cardíaca congestiva pré-existente
UA2002032397A UA76702C2 (uk) 1999-08-27 2000-08-25 Застосування раміприлу для запобігання розвитку застійної серцевої недостатності
HU0202461A HU229107B1 (en) 1999-08-27 2000-08-25 Use of ramipril in prevention of congestive heart failure
TR2002/02467T TR200202467T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formulasyonlar
AT04006330T ATE554761T1 (de) 1999-08-27 2000-08-25 Verwendung von ramipril zur vorbeugung von diabetes bei einem patienten ohne bestehendes kongestives herzversagen
MXPA02001633A MXPA02001633A (es) 1999-08-27 2000-08-25 Formulaciones farmaceuticas y su uso en la prevencion de ataque, diabetes y/o falla cardiaca congestiva.
SI200030766T SI1212081T2 (sl) 1999-08-27 2000-08-25 Uporaba ramiprila za preprečevanje kongestivne srčne odpovedi
AT00965898T ATE307604T1 (de) 1999-08-27 2000-08-25 Verwendung von ace inhibitoren zur prophylaxe von kongestivem herzversagen
SI200031084T SI1925303T1 (sl) 1999-08-27 2000-08-25 Uporaba angiotenzin II tip 1 receptorskih antagonistov za preprečevanje diabetesa
CNA2008101259535A CN101537181A (zh) 1999-08-27 2000-08-25 药物制剂及其在预防中风、糖尿病和/或充血性心衰中的应用
RU2002107673/15A RU2272651C2 (ru) 1999-08-27 2000-08-25 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности
IL148126A IL148126A (en) 1999-08-27 2000-08-25 Use of Rampril or Ramiprilat or their pharmaceutical salt preparation to prepare a heart failure medication in patients without previous heart failure
AU76484/00A AU7648400A (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
TR2002/02466T TR200202466T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar.
CZ20020644A CZ303433B6 (cs) 1999-08-27 2000-08-25 Použití ramiprilu, ramiprilátu nebo jejich farmaceuticky prijatelných derivátu
SI200031069T SI1437131T1 (sl) 1999-08-27 2000-08-25 Uporaba ramiprila za preprečevanje diabetesa pri bolniku brez predhodno obstoječe kongestivne srčne opovedi
JP2001519887A JP4843172B2 (ja) 1999-08-27 2000-08-25 医薬処方物および卒中、糖尿病および／またはうっ血性心不全の予防におけるその使用
ES04006330T ES2386141T3 (es) 1999-08-27 2000-08-25 Uso de ramipril para la prevención de diabetes en un paciente sin insuficiencia cardíaca congestiva preexistente
ES00965898.0T ES2250192T5 (es) 1999-08-27 2000-08-25 Uso de ramipril en la prevención de la insuficiencia cardiaca congestiva
EP04006330A EP1437131B1 (fr) 1999-08-27 2000-08-25 Utilisation de ramipril pour la prévention du diabète chez un patient sans insuffisance cardiaque congestive préexisitante
DK04006330.7T DK1437131T3 (da) 1999-08-27 2000-08-25 Anvendelse af ramipril til forebyggelse af diabetes hos en patient uden præeksisterende kongestiv hjerteinsufficiens
NZ571901A NZ571901A (en) 1999-08-27 2000-08-25 Use of ramipril or ramiprilat for the prevention of congestive heart failure
EP10010670A EP2277519A3 (fr) 1999-08-27 2000-08-25 Utilisation d'antagonistes du récepteur Angiotensin II Type 1 pour prévenir l'accident cérébrovasculaire, le diabète et/ou l'insuffisance cardiaque globale
RS3602A RS52907B (en) 1999-08-27 2000-08-25 USE OF ACE INHIBITORS FOR THE PREVENTION OF CONGESTIVE HEART INSUFFICIENCY
SK270-2002A SK288239B6 (sk) 1999-08-27 2000-08-25 Použitie ramiprilu na výrobu liečiva na prevenciu kongestívneho zlyhania srdca
PCT/EP2000/008341 WO2001015673A2 (fr) 1999-08-27 2000-08-25 Formulations pharmaceutiques et utilisations de ces dernieres pour prevenir l'accident cerebrovasculaire, le diabete et/ou l'insuffisance cardiaque globale
TR2002/02463T TR200202463T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar
EEP200200085A EE05130B1 (et) 1999-08-27 2000-08-25 Angiotensiini konvertaasi inhibiitori kasutamine ravimina kongestiivse sdamepuudulikkuse „rahoidmiseks
CA002382387A CA2382387C (fr) 1999-08-27 2000-08-25 Formulations pharmaceutiques et utilisations de ces dernieres pour prevenir l'accident cerebrovasculaire, le diabete et/ou l'insuffisance cardiaque globale
KR1020027002521A KR20020060167A (ko) 1999-08-27 2000-08-25 뇌졸중, 당뇨병 및/또는 울혈성 심부전증의 예방을 위한약제학적 제형 및 이의 용도
KR1020087007837A KR20080035703A (ko) 1999-08-27 2000-08-25 뇌졸중, 당뇨병 및/또는 울혈성 심부전증 예방용 약제학적조성물
ES08004265.8T ES2525699T3 (es) 1999-08-27 2000-08-25 Uso de antagonistas del receptor de tipo 1 de la angiotensina II para la prevención de diabetes
DK00965898.0T DK1212081T4 (da) 1999-08-27 2000-08-25 Anvendelse af ACE-inhibitorer i forebyggelse af kongestivt hjertesvigt
MEP-282/08A MEP28208A (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
YU3602A YU3602A (sh) 1999-08-27 2002-01-16 Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primena
BG11047909A BG110479A (en) 1999-08-27 2002-01-18 Pharmaceutical preparations and their use in the prevention of stroke, diabetes and/or congestive heart failure
BG106319A BG66115B1 (bg) 1999-08-27 2002-01-18 Използване на рамиприл или негова фармацевтично приемлива сол за предотвратяване на конгестивна сърдечна недостатъчност
NO20020850A NO329245B1 (no) 1999-08-27 2002-02-21 Anvendelse av ramipril eller ramiprilat for fremstilling av medikament
ZA200201471A ZA200201471B (en) 1999-08-27 2002-02-21 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure.
HR20020169A HRP20020169A2 (en) 1999-08-27 2002-02-26 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
HK03102600.5A HK1050327A1 (en) 1999-08-27 2003-04-10 Use of an angiotensin converting enzyme inhibitor in the manufacture of a medicament for the prevention or reduction of the risk of congestive heart failure
AU2005203694A AU2005203694A1 (en) 1999-08-27 2005-08-17 Pharmaceutical Formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
RU2005128124/15A RU2378018C2 (ru) 1999-08-27 2005-09-08 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности
UAA200601774A UA88270C2 (ru) 1999-08-27 2006-02-20 Фармацевтический препарат и его применение для профилактики удара, диабета
US11/415,137 US20060194868A1 (en) 1999-08-27 2006-05-02 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and /or congestive heart failure
US12/027,938 US20080125472A1 (en) 1999-08-27 2008-02-07 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
AU2009200551A AU2009200551B2 (en) 1999-08-27 2009-02-12 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
US12/457,589 US20090258919A1 (en) 1999-08-27 2009-06-16 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / or congestive heart failure
US12/615,588 US20100267798A1 (en) 1999-08-27 2009-11-10 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
NO20100569A NO20100569L (no) 1999-08-27 2010-04-20 Farmasoytiske formuleringer og anvendelse derav i forebyggelsen av slag, diabetes og/eller kongestivt hjertesvikt
US12/957,777 US20110263619A1 (en) 1999-08-27 2010-12-01 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
CY20121100657T CY1112987T1 (el) 1999-08-27 2012-07-24 Χρηση της ραμιπριλης για την προληψη του διαβητη σε ασθενη χωρις προυπαρχουσα συμφορητικη καρδιακη ανεπαρκεια
US13/673,852 US20130317047A1 (en) 1999-08-27 2012-11-09 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
CY20141101082T CY1115869T1 (el) 1999-08-27 2014-12-23 Χρηση ανταγωνιστων του υποδοχεα τυπου 1 της αγγειοτενσινης ii για την προληψη του διαβητη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use

Publications (1)

Publication Number Publication Date
SE9903028D0 true SE9903028D0 (sv) 1999-08-27

Family

ID=20416770

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use

Country Status (36)

Country Link
US (6) US20060194868A1 (fr)
EP (4) EP1925303B1 (fr)
JP (1) JP4843172B2 (fr)
KR (2) KR20020060167A (fr)
CN (2) CN101537181A (fr)
AT (2) ATE307604T1 (fr)
AU (3) AU7648400A (fr)
BG (2) BG66115B1 (fr)
BR (1) BR0013540A (fr)
CA (1) CA2382387C (fr)
CY (2) CY1112987T1 (fr)
CZ (1) CZ303433B6 (fr)
DE (1) DE60023518T3 (fr)
DK (3) DK1437131T3 (fr)
EE (1) EE05130B1 (fr)
ES (3) ES2386141T3 (fr)
HK (1) HK1050327A1 (fr)
HR (1) HRP20020169A2 (fr)
HU (1) HU229107B1 (fr)
IL (1) IL148126A (fr)
ME (1) MEP28208A (fr)
MX (1) MXPA02001633A (fr)
NO (2) NO329245B1 (fr)
NZ (1) NZ571901A (fr)
PL (1) PL353066A1 (fr)
PT (2) PT1437131E (fr)
RS (1) RS52907B (fr)
RU (2) RU2272651C2 (fr)
SE (1) SE9903028D0 (fr)
SI (3) SI1925303T1 (fr)
SK (1) SK288239B6 (fr)
TR (5) TR200202467T2 (fr)
UA (2) UA76702C2 (fr)
WO (1) WO2001015673A2 (fr)
YU (1) YU3602A (fr)
ZA (1) ZA200201471B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60022525T2 (de) * 1999-08-30 2006-06-14 Sanofi Aventis Deutschland Ramipril zur vorbeugung von kardiovaskulären vorfällen
MXPA03008636A (es) 2001-03-26 2003-12-08 Kotobuki Pharmaceutical Co Ltd Derivados de isoquinuclidina, metodo para fabricar los mismos y agentes terapeuticos que contienen estos compuestos.
EP1438043A2 (fr) * 2001-10-17 2004-07-21 Aventis Pharma Deutschland GmbH Methode de reduction du diabete type 2 chez des patients a risque eleve
US6844361B2 (en) 2002-02-04 2005-01-18 Aventis Pharma Deutschland Gmbh Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (fr) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Utilisation d'un agent bloquant du récepteur AT1 de l'angiotensine II, seul ou combiné avec un thiazide ou l'angiotensine II dans le traitement des accidents vasculaires cérébraux
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CA2458288A1 (fr) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Methode et compose pour reduire l'incidence du diabete chez un sujet qui souffre d'une insuffisance cardiaque chronique
RU2367442C2 (ru) 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
AU2004290925B2 (en) * 2003-11-18 2010-07-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
EP1729749A2 (fr) * 2004-03-17 2006-12-13 Novartis AG Utilisation d'inhibiteur de la renine en therapie
MX2007005373A (es) * 2004-11-05 2007-08-14 King Pharmaceuticals Res & Dev Composiciones estabilizadas de ramipril y metodos para elaborarlas.
CA2675901A1 (fr) * 2005-10-13 2007-04-19 Duke University Compositions pour le traitement et la prevention de maladies cardiaques et procedes d'utilisation de celles-ci
CA2661598A1 (fr) * 2006-08-28 2008-03-06 Sanofi-Aventis Deutschland Gmbh Procedes de diminution des taux de glucose
EP2679224A1 (fr) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Modulation d'acide nitro-oléique du diabète de type II
EP2280928B1 (fr) 2008-05-01 2018-07-25 Complexa Inc. Acides gras à substitution vinyle
CN102099024B (zh) 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2010022249A2 (fr) 2008-08-20 2010-02-25 Ensemble Discovery Corporation Composés destinés à l’inhibition du facteur de nécrose tumorale alpha
EP2459189A4 (fr) 2009-07-31 2013-01-16 Univ Pittsburgh Acides gras comme agents anti-inflammatoires
CA2781276A1 (fr) 2009-10-02 2011-04-07 Complexa, Inc. Heteroatome contenant des acides gras substitues
CN103118611B (zh) 2010-05-14 2015-09-23 萨班吉大学 一种用于在医疗中使用水力空化的设备
WO2013028501A1 (fr) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Polythérapie au moyen de lipides nitrés et d'inhibiteurs du système rénine-angiotensine-aldostérone
WO2016176338A1 (fr) * 2015-04-30 2016-11-03 The Trustees Of Columbia University In The City Of New York Ligands ras de petites molécules
EP4335497A3 (fr) 2015-07-07 2024-05-01 H. Lundbeck A/S Inhibiteur de pde9 présentant un squelette d'imidazo pyrazinone pour le traitement de maladies périphériques
MX2018004043A (es) 2015-10-02 2018-11-09 Complexa Inc Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
CN110833620A (zh) * 2018-08-15 2020-02-25 王镕 血管紧张素转化酶抑制剂在防治自身免疫性疾病及相应的并发症中的用途
KR20230137654A (ko) * 2022-03-22 2023-10-05 주식회사 메디포럼 뇌졸중의 예방 및 치료용 조성물

Family Cites Families (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
DE3413710A1 (de) 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
EP0241201A3 (fr) * 1986-04-07 1990-05-23 Merck & Co. Inc. Inhibiteurs de l'enzyme de conversion de l'angiotensine, utiles pour prolonger la survie des mammifères avec un défaut cardiaque congestif
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (fr) 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
DE3704661A1 (de) 1987-02-14 1988-08-25 Hoechst Ag Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (fr) 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
EP0331014A3 (fr) * 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH L'utilisation des inhibiteurs de l'enzyme de conversion pour la prophylaxie du diabète
US5217958A (en) * 1988-03-03 1993-06-08 E. R. Squibb & Sons, Inc. 1,2-hydroxy phosphonates and derivatives thereof
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
CA2003382A1 (fr) * 1988-11-21 1990-05-21 Hollis D. Kleinert Methode de traitement de maladies vasculaires
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
CA2016467A1 (fr) * 1989-06-05 1990-12-05 Martin Eisman Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
EP0955294B1 (fr) 1989-06-14 2003-09-24 Smithkline Beecham Corporation Acides imidazoalcénoiques
CA2018443A1 (fr) 1989-06-14 1990-12-14 Joseph A. Finkelstein Acides imidazolyl-alkenoiques
KR950009860B1 (ko) 1989-06-30 1995-08-29 이. 아이. 듀퐁 드 네모아 앤드 캄파니 융합된 환 아릴 치환된 이미다졸과 약제학적으로 허용되는 이의 염, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물
KR0163595B1 (ko) 1989-06-30 1998-12-01 미리암디, 메코너헤이 치환된 이미다졸
CA2020073A1 (fr) 1989-07-03 1991-01-04 Eric E. Allen Quinazolinones substitues comme antagonistes de l'angiotensine ii
US5164407A (en) 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE69024556T2 (de) 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
DE69013607T2 (de) 1989-08-02 1995-03-02 Takeda Chemical Industries Ltd Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung.
YU155290A (sh) 1989-08-11 1993-05-28 Imperial Chemical Industries Plc. Dusikove spojine
DE3926606A1 (de) * 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
US5100897A (en) 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0424317A3 (en) 1989-10-19 1991-09-25 Ciba-Geigy Ag Pyrimidines
US5212165A (en) * 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
CA2027937A1 (fr) 1989-10-25 1991-04-26 Richard M. Keenan 5-¬(tetrazolyle)alcenyle|imidazoles substitues
CA2026686A1 (fr) * 1989-10-30 1991-05-01 Werner Tschollar Methode de prevention de l'apparition du diabete de type 11 par l'emploi d'un inhibiteur de l'enzyme de conversion
IL96019A0 (en) 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2028925A1 (fr) 1989-11-06 1991-05-07 Gerald R. Girard Derives substitues de la n-(imidazolyl)alkylalanine
PT95899A (pt) 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
IE903911A1 (en) 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
JPH03223281A (ja) 1989-12-01 1991-10-02 Glaxo Group Ltd ベンゾチオフェン誘導体
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
GB8927277D0 (en) 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5104891A (en) 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0434038A1 (fr) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Dérivés condensés d'imidazole, leur préparation et leur utilisation
EP0435827A3 (en) 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
CA2032289A1 (fr) 1989-12-29 1991-06-30 Joseph A. Finkelstein 5-(alkyl)carboxamideimidazoles substitues
JP2726563B2 (ja) 1990-02-13 1998-03-11 メルク・エンド・カムパニー・インコーポレーテツド 置換ベンジル要素を含むトリアゾールアンギオテンシン▲ｉｉ▼拮抗物質
JPH05504359A (ja) 1990-02-13 1993-07-08 メルク・エンド・カムパニー・インコーポレーテツド 置換ベンジル部分を含むイミダゾールアンギオテンシン２拮抗物質
EP0517812A4 (en) 1990-02-13 1995-10-18 Merck & Co Inc Angiotensin ii antagonists incorporating a substituted benzyl element
WO1991012696A1 (fr) 1990-02-14 1991-08-22 Siemens Aktiengesellschaft Procede et circuit de demodulation de signaux de television en couleurs a codage secam a frequence elementaire couplee aux lignes
DE69129998T2 (de) 1990-02-15 1998-12-24 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren Herstellung und Verwendung
DE19675036I2 (de) 1990-02-19 2004-10-21 Novartis Ag Acylverbindungen.
CA2036618C (fr) 1990-02-22 2002-10-29 Akira Morimoto Derives thiophene a anneaux condenses, leur production et leur utilisation
DE4006693A1 (de) 1990-03-01 1991-09-05 Schering Ag Neue benzimidazolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5044166A (en) 1990-03-05 1991-09-03 Membrane Technology & Research, Inc. Refrigeration process with purge and recovery of refrigerant
CA2037630C (fr) 1990-03-07 2001-07-03 Akira Morimoto Composes heterocycliques renfermant de l'azote, methode de production et applications correspondantes
GB9005354D0 (en) 1990-03-09 1990-05-02 Glaxo Group Ltd Chemical compounds
FR2659655B1 (fr) 1990-03-19 1992-07-24 Union Pharma Scient Appl Nouveaux derives d'oxypyrazole antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
CA2079343A1 (fr) 1990-03-30 1991-10-01 Eric E. Allen Pyrazoles, isoxazoles et isothiazoles substituees
CA2079344A1 (fr) 1990-03-30 1991-10-01 Eric E. Allen Pyrimidines, pyrimidinones et pyridopyrimidines substituees
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
AU7759591A (en) 1990-04-13 1991-11-11 Smithkline Beecham Corporation Substituted benzimidazoles
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5098920A (en) 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
GB9010394D0 (en) 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
CA2041763A1 (fr) 1990-05-11 1991-11-12 Sheih-Shung T. Chen Procede de transformation microbienne pour les antihypertenseurs
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
WO1991018888A1 (fr) 1990-05-25 1991-12-12 G.D. Searle & Co. Composes de 1,2,4-triazolones a substitution n utilises dans le traitement de troubles cardiovasculaires
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5166143A (en) * 1990-05-31 1992-11-24 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
AU653524B2 (en) 1990-06-08 1994-10-06 Roussel-Uclaf New imidazole derivatives, their preparation process, the new intermediates obtained, their use as medicaments and the pharmaceutical compositions containing them
DK0461039T3 (da) 1990-06-08 1999-06-14 Hoechst Marion Roussel Inc Nye benzimidazolafledte forbindelser, fremgangsmåde til deres fremstilling, de opnåede mellemprodukter, deres anvendelse so
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
AU7983691A (en) 1990-06-15 1992-01-07 G.D. Searle & Co. 1h-substituted-imidazo{4,5-d}pyridazine compounds for treatment of cardiovascular disorders
CA2051705A1 (fr) 1990-06-19 1991-12-20 Kiyoaki Katano Derives de la pyridine, antagonistes de l'angiotensine ii
JPH05509086A (ja) 1990-06-22 1993-12-16 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー イミダゾールアンジオテンシン―２受容体拮抗薬による慢性腎不全の治療
NZ238688A (en) 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
IE912114A1 (en) 1990-07-02 1992-01-15 Union Pharma Scient Appl Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present
IL98319A (en) 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5137902A (en) 1990-07-13 1992-08-11 E. I. Du Pont De Nemours And Company 4-alkylimidazole derivatives and anti-hypertensive use thereof
CA2044806A1 (fr) 1990-07-18 1992-01-19 Roland Jaunin Derives de purine
CA2047029A1 (fr) 1990-07-19 1992-01-20 Shieh-Shung T. Chen Procede de transformation microbienne pour des produits antihypertenseurs
DE4023215A1 (de) 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
RU1836357C (ru) 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами
NZ239161A (en) 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
EP0470543A1 (fr) 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Imidazoles hétérocycliques, médicaments contenant ces composés et procédés pour leur préparation
US5217985A (en) 1990-08-28 1993-06-08 G. D. Searle & Co. Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension
CA2048699A1 (fr) * 1990-09-04 1992-03-05 Abraham Sudilovsky Methode de prevention ou de traitement des maladies cerebro-vasculaires faisant appel au ceronapril
WO1992004343A1 (fr) 1990-09-04 1992-03-19 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive de tetrahydrobenzazole
IL99372A0 (en) 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
IE912956A1 (en) 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
US5140036A (en) 1990-09-19 1992-08-18 G. D. Searle & Co. 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5242939A (en) 1990-09-28 1993-09-07 Warner-Lambert Company Anilide derivatives with angiotensin ii antagonist properties
EP0481614A1 (fr) 1990-10-01 1992-04-22 Merck & Co. Inc. Pyridopyrimidinones substituées et hétérocyles apparantés comme antagonistes de la angiotensine II
US5126342A (en) 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5470975A (en) * 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
CA2053148A1 (fr) 1990-10-16 1992-04-17 Karnail Atwal Derives de la dihydropyrimidine
US5430145A (en) 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (fr) 1990-10-18 2002-04-02 Timothy P. Burkholder Derives de mercaptoacetylamide utiles comme inhibiteurs de l'encephalinase et de l'ace
CA2052014A1 (fr) * 1990-10-19 1992-04-20 Henry Y. Pan Methode de prevention des complications du diabete faisant appel a un hypocholesterolemiant seul ou en association avec un inhibiteur de l'enzyme de conversion de l'angiotensine
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
AU9024591A (en) 1990-10-25 1992-05-26 G.D. Searle & Co. Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders
AU636066B2 (en) 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
PH31175A (en) 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
DE4036645A1 (de) 1990-11-16 1992-05-21 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung
DE4036706A1 (de) 1990-11-17 1992-05-21 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
GB9025123D0 (en) 1990-11-19 1991-01-02 Ici Plc Nitrogen compounds
GB9026006D0 (en) 1990-11-29 1991-01-16 Glaxo Group Ltd Chemical compounds
WO1992009278A1 (fr) 1990-11-30 1992-06-11 Smithkline Beecham Corporation Imidazoles 5-aryle substitues
CA2057089A1 (fr) 1990-12-07 1992-06-08 Eric E. Allen Derives de substitution de pyrazolopyrimidines and d'imidazopyridazines, antagonistes de l'angiotensine ii
EP0563238B1 (fr) 1990-12-14 2002-05-22 Smithkline Beecham Corporation Acides imidazolyl-alcenoiques
AU657498B2 (en) 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
US5175180A (en) 1990-12-20 1992-12-29 G. D. Searle & Co. N-substituted n-(alpha-triazolyl-toluyl)pyrrole compounds and use for treatment of circulatory disorders
CA2058198A1 (fr) 1991-01-04 1992-07-05 Adalbert Wagner Procede de preparation et utilisation de derives d'azole
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
US5290780A (en) 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
AT395853B (de) 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
JP3531944B2 (ja) 1991-02-07 2004-05-31 アベンティス・ファーマ・ソシエテ・アノニム 新規のベンジル基で置換された窒素系二環式誘導体及びその製造方法
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9102804D0 (en) 1991-02-11 1991-03-27 Ici Plc Heterocyclic derivatives
IE920175A1 (en) 1991-02-11 1992-08-12 Zeneca Ltd Nitrogen heterocycles
GB9102803D0 (en) 1991-02-11 1991-03-27 Ici Plc Pyridine compounds
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
FR2672892B1 (fr) 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
CA2061159A1 (fr) 1991-02-26 1992-08-27 Michael A. Poss Derives imidazole et benzimidazole
FR2673427B1 (fr) 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
EP0502575A1 (fr) 1991-03-06 1992-09-09 Merck & Co. Inc. 1-(2H)-Isoquinoleinones substituées
EP0503838A3 (en) 1991-03-08 1992-10-07 Merck & Co. Inc. Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
EP0505098A1 (fr) 1991-03-19 1992-09-23 Merck & Co. Inc. Dérivés d'imidazole ayant des groupes fonctionnels acides comme angiotensin II antagonistes
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5187179A (en) 1991-03-22 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole
AU1417092A (en) 1991-03-25 1992-10-21 Glaxo Group Limited 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity
US5128327A (en) 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
DE4110019C2 (de) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5157040A (en) 1991-04-05 1992-10-20 Merck & Co., Inc. Substituted quinolines as angiotensin ii antagonists
US5164403A (en) 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
US5155117A (en) 1991-04-12 1992-10-13 G. D. Searle & Co. 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders
TW274551B (fr) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
US5252574A (en) 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
DE4200954A1 (de) 1991-04-26 1992-10-29 Bayer Ag Heterocyclisch substituierte phenylessigsaeurederivate
CZ227093A3 (en) 1991-04-29 1994-03-16 Merck & Co Inc Mixture suitable for the preparation of tablets by direct moulding
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
US5198438A (en) 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5506361A (en) * 1991-05-08 1996-04-09 Theupjohn Company Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
JPH05112533A (ja) 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5223501A (en) 1991-05-10 1993-06-29 Merck & Co., Inc. Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
US5162340A (en) 1991-05-10 1992-11-10 Merck & Co., Inc. Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
GB9110532D0 (en) 1991-05-15 1991-07-03 Smithkline Beecham Corp Chemical compounds
GB9110625D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
TW221997B (fr) 1991-05-16 1994-04-01 Glaxo Group Ltd
GB9110623D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110635D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
EP0514192A1 (fr) 1991-05-16 1992-11-19 Glaxo Group Limited Dérivés de benzofuranne à activité anti-hypertensive, substituées par des groupes N-pyrimidinyle- ou N-imidazolyle-methyle variables
FR2676734B1 (fr) 1991-05-23 1995-05-19 Roussel Uclaf Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
WO1992021666A1 (fr) 1991-05-31 1992-12-10 Laboratoires Upsa Derives de thiazole antagonistes de recepteurs a l'angiotensine ii
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
US5175164A (en) 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5210211A (en) 1991-06-21 1993-05-11 Warner-Lambert Company 4-(1h-pyrrol-1-yl) imidazoles with angiotension ii antagonist activity
GB9113626D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic compounds
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
IL102365A0 (en) 1991-07-03 1993-01-14 Merck & Co Inc Substituted triazolinones,their preparation and pharmaceutical compositions containing them
FR2678618B1 (fr) 1991-07-05 1993-11-05 Upsa Laboratoires Nouveaux derives de triazolo pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
AU2338992A (en) 1991-07-26 1993-03-02 G.D. Searle & Co. Carbonate-substituted imidazo(4,5-d) pyridazine compounds for treatment of cardiovascular disorders
IT1250749B (it) 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
WO1993003040A1 (fr) 1991-08-05 1993-02-18 Taisho Pharmaceutical Co., Ltd. Derive de thienopyrimidin-4-one
US5225401A (en) 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5246944A (en) 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
EP0528762B1 (fr) 1991-08-15 1997-05-07 Novartis AG Acides aminés N-acyl-N-hétérocyclyl- ou naphtyl-alkyl comme angiotensine II antagonistes
ES2110458T3 (es) 1991-09-20 1998-02-16 Lgl Electronics Spa Dispositivo autoajustable para frenar el hilo en las unidades alimentadoras de trama.
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
AU657793B2 (en) 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
ZA927211B (en) 1991-09-27 1993-03-24 Merrell Dow Pharma Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE.
JPH06107661A (ja) * 1991-10-24 1994-04-19 Upjohn Co:The イミダゾール誘導体およびこれを有効成分とする医薬組成物
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5977160A (en) * 1992-04-10 1999-11-02 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5552397A (en) 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
HU223663B1 (hu) 1992-05-15 2004-11-29 Merrel Dow Pharmaceuticals Inc. Enkefalináz és ACE gátló hatású 9-[(2-acetil-tio-3-fenil)-propanoil-amino]-piridazo[1,2-a][1,2]diazepin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AU675660B2 (en) * 1992-07-17 1997-02-13 Merck & Co., Inc. Substituted biphenylmethylimidazopyridines
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
US5504080A (en) 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
DE4308504A1 (de) * 1993-03-18 1994-09-22 Knoll Ag Neue Verwendung einer Kombination aus Verapamil und Trandolapril
DE4309553A1 (de) * 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
CN1110865A (zh) 1993-06-11 1995-10-25 卫材株式会社 氨基酸衍生物
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362727A (en) 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
ES2079315B1 (es) * 1994-02-24 1996-10-16 Uriach & Cia Sa J Nuevas imidazopiridinas.
ES2105939B1 (es) * 1994-08-02 1998-07-01 Uriach & Cia Sa J Nuevos pirazoles con actividad antagonista de la angiotensina ii.
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
BR9604882A (pt) * 1995-02-10 1998-05-19 Searle & Co Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5656603A (en) * 1995-05-31 1997-08-12 Loyola University Of Chicago Aminopeptidase P inhibitors and uses thereof
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
GB2308064A (en) * 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
WO1997027745A1 (fr) * 1996-01-31 1997-08-07 Technology Licensing Co. L.L.C. Procede de diagnostic et de traitement, compositions et appareils connexes
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique
WO1997049392A1 (fr) * 1996-06-24 1997-12-31 Merck & Co., Inc. Composition a base d'enalapril et de losartan
KR20000070046A (ko) * 1997-01-10 2000-11-25 폴락 돈나 엘. 심부전증을 치료하기 위한, 안지오텐신 ⅱ 길항제를 포함하는 약제학적 조성물
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
KR100572080B1 (ko) * 1997-10-17 2006-04-17 유로진 리미티드 레닌-안지오텐신계 억제제의 용도
US6097772A (en) * 1997-11-24 2000-08-01 Ericsson Inc. System and method for detecting speech transmissions in the presence of control signaling
JPH11222439A (ja) * 1998-02-03 1999-08-17 Dainippon Pharmaceut Co Ltd 脳血管攣縮抑制薬
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
EP1870098A3 (fr) * 1998-07-10 2010-07-07 Novartis Ag Utilisation combinée de valsaratan et bloqueurs du canal de calcium à buts thérapeutiques
DE19913528A1 (de) * 1998-12-21 2000-06-29 Sanol Arznei Schwarz Gmbh Neue Verwendung von Moexipril
AU5016200A (en) * 1999-05-21 2000-12-12 Myriad Genetics, Inc. Diabetes gene
DE60022525T2 (de) * 1999-08-30 2006-06-14 Sanofi Aventis Deutschland Ramipril zur vorbeugung von kardiovaskulären vorfällen
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
PL370270A1 (en) * 2001-11-23 2005-05-16 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
ITBO20030050A1 (it) * 2003-02-06 2004-08-07 Ima Spa Macchina per il trattamento di prodotti farmaceutici.

Also Published As

Publication number Publication date
PT1437131E (pt) 2012-07-12
HK1050327A1 (en) 2003-06-20
TR200202463T2 (tr) 2003-01-21
RU2002107673A (ru) 2004-01-10
ME00181B (me) 2010-10-10
CY1115869T1 (el) 2017-01-25
US20130317047A1 (en) 2013-11-28
US20080125472A1 (en) 2008-05-29
DE60023518D1 (de) 2005-12-01
RU2272651C2 (ru) 2006-03-27
DK1437131T3 (da) 2012-08-06
DK1212081T3 (da) 2006-01-16
SK2702002A3 (en) 2002-09-10
JP2003508426A (ja) 2003-03-04
MEP28208A (en) 2010-10-10
EP1212081A2 (fr) 2002-06-12
EE05130B1 (et) 2009-02-16
CZ303433B6 (cs) 2012-09-12
ZA200201471B (en) 2003-05-28
AU2009200551B2 (en) 2010-09-30
ES2250192T5 (es) 2014-06-27
EP2277519A3 (fr) 2011-09-07
AU2009200551A1 (en) 2009-03-05
PT1925303E (pt) 2014-12-18
YU3602A (sh) 2004-12-31
AU2005203694A1 (en) 2005-09-08
HU229107B1 (en) 2013-07-29
JP4843172B2 (ja) 2011-12-21
MXPA02001633A (es) 2002-08-06
EP1437131B1 (fr) 2012-04-25
ATE307604T1 (de) 2005-11-15
EP1212081B8 (fr) 2005-12-28
KR20080035703A (ko) 2008-04-23
TR200200518T2 (tr) 2002-06-21
CN101537181A (zh) 2009-09-23
NO20020850L (no) 2002-02-21
CA2382387C (fr) 2005-06-21
CZ2002644A3 (cs) 2002-05-15
BG110479A (en) 2010-01-29
BG106319A (bg) 2002-12-29
EP2277519A2 (fr) 2011-01-26
ES2525699T3 (es) 2014-12-29
HUP0202461A3 (en) 2003-04-28
NO20020850D0 (no) 2002-02-21
WO2001015673A2 (fr) 2001-03-08
EP1925303B1 (fr) 2014-09-24
AU7648400A (en) 2001-03-26
DE60023518T2 (de) 2006-07-06
SI1212081T2 (sl) 2014-08-29
RS52907B (en) 2014-02-28
EE200200085A (et) 2003-04-15
IL148126A0 (en) 2002-09-12
US20090258919A1 (en) 2009-10-15
CA2382387A1 (fr) 2001-03-08
TR200202467T2 (tr) 2002-12-23
IL148126A (en) 2014-12-31
US20110263619A1 (en) 2011-10-27
DK1925303T3 (en) 2015-01-05
US20060194868A1 (en) 2006-08-31
KR20020060167A (ko) 2002-07-16
ATE554761T1 (de) 2012-05-15
EP1925303A3 (fr) 2010-12-08
ES2250192T3 (es) 2006-04-16
NZ571901A (en) 2010-05-28
ES2386141T3 (es) 2012-08-10
RU2005128124A (ru) 2007-03-20
EP1212081B2 (fr) 2014-04-02
UA76702C2 (uk) 2006-09-15
RU2378018C2 (ru) 2010-01-10
EP1925303A2 (fr) 2008-05-28
EP1437131A1 (fr) 2004-07-14
EP1212081B1 (fr) 2005-10-26
DE60023518T3 (de) 2014-08-28
BR0013540A (pt) 2002-04-30
WO2001015673A3 (fr) 2002-03-07
TR200202466T2 (tr) 2002-12-23
NO20100569L (no) 2002-02-21
CY1112987T1 (el) 2016-04-13
BG66115B1 (bg) 2011-05-31
UA88270C2 (ru) 2009-10-12
SI1437131T1 (sl) 2012-09-28
DK1212081T4 (da) 2014-07-07
CN100408093C (zh) 2008-08-06
US20100267798A1 (en) 2010-10-21
NO329245B1 (no) 2010-09-20
SI1212081T1 (sl) 2006-06-30
HUP0202461A2 (hu) 2002-12-28
SK288239B6 (sk) 2015-02-03
HRP20020169A2 (en) 2005-10-31
PL353066A1 (en) 2003-10-06
CN1384756A (zh) 2002-12-11
TR200202464T2 (tr) 2003-01-21
SI1925303T1 (sl) 2015-01-30

Similar Documents

Publication Publication Date Title
SE9903028D0 (sv) New use
DE60022525T2 (de) Ramipril zur vorbeugung von kardiovaskulären vorfällen
WO2003020202A3 (fr) Methode permettant de reduire l'hypertension et l'insuffisance cardiaque
WO2001082919A3 (fr) Procedes et composes d'inhibition de la calpaine
Whelton et al. Once‐daily lisinopril compared with twice‐daily captopril in the treatment of mild to moderate hypertension: Assessment of office and ambulatory blood pressures
WO2002056837A3 (fr) Inhibition de proteines phosphatases dans le traitement de l'insuffisance cardiaque
Kopecky Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis
WO2003032963A3 (fr) Methode de reduction du diabete type 2 chez des patients a risque eleve
Fariello et al. A004: Candesartan, ABPM and structural--functional parameters in essential hypertensive patients
HUP0303836A2 (hu) Angiotenzin antagonisták és ACE inhibitorok gyógyszerészeti kombinációja és ezeket tartalmazó gyógyszerkészítmények
NO20013753L (no) Anvendelse av moxonidin til behandling etter hjerteinfarkt
Bankhead Antihypertensive therapy: friend or foe in stroke?
WO2004075893A8 (fr) Methode de traitement d'une insuffisance cardiaque et/ou renale utilisant un inhibiteur calcique et un inhibiteur de l'enzyme de conversion de l'angiotensine ou un inhibiteur du recepteur de l'angiotensine ii
Stergiou et al. A005: Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension
UA37953A (uk) Спосіб поліхіміотерапії вперше виявлених хворих деструктивним туберкульозом легень
AR022475A1 (es) Metodo para la prevencion o reduccion de eventos cardiovasculares asociados con intervencion coronaria.
Golden et al. Three false truths?